Videman T, Sonck T, Jänne J
Med Sci Sports. 1979 Fall;11(3):266-9.
Nine ski-jumpers from the Finnish Olympic team were given 40 mg of oxprenolol or placebo on a cross-over double-blind basis when participating in four internal competitions. Six ski-jumpers improved their performances when on oxprenolol. The improvement was mainly seen in the lengthening of the jumps. The tachycardia, apparently evoked by the emotional and physical strain associated with the actual jump, approached rather extreme levels (up to 170 beats/min) immediately after landing. The enhancement in the heart rate was effectively prevented by a gentle beta-blockade. The most common unwanted effect recorded was numbness in the legs after climbing up to the tower platform, reported 9 times out of 18 possible occasions after oxprenolol but never after placebo. The fact that three of the jumpers (out of 9) performed worse when on oxprenolol makes the toxic/benefit ratio (1:2) unacceptably high for the medication.
芬兰奥运代表队的九名跳台滑雪运动员在参加四项内部比赛时,以交叉双盲的方式服用了40毫克氧烯洛尔或安慰剂。六名跳台滑雪运动员在服用氧烯洛尔后成绩有所提高。这种提高主要体现在跳跃距离的延长上。与实际跳跃相关的情绪和身体压力显然引发了心动过速,着陆后心率立即接近相当高的水平(高达170次/分钟)。温和的β受体阻滞剂有效地预防了心率的升高。记录到的最常见不良反应是爬上跳台后腿部麻木,服用氧烯洛尔后在18次可能的情况中有9次出现,而服用安慰剂后从未出现过。9名运动员中有3名在服用氧烯洛尔后表现更差,这使得该药物的毒/益比(1:2)高得令人无法接受。